Causes of and prevention strategies for hepatocellular carcinoma.

Calogero Camma', Giuseppe Cabibbo, Chiara Genco, Marcello Fabio Maida, Michela Antonucci

Risultato della ricerca: Article

36 Citazioni (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behavior treatment and/or insulin-sensitizing drugs can be envisaged. Vaccination against HBV is the most efficient primary prevention measure currently available to reduce the HCC incidence and mortality in high-incidence areas, while data on the role of interferon (IFN) and nucleos(t)ide analogues (NUC) are still controversial. The pooling of data from the literature suggests a slight preventive effect of antiviral therapy on HCC development in patients with HCV-related cirrhosis, but the preventive effect is limited to sustained virological responders.
Lingua originaleItalian
pagine (da-a)374-383
Numero di pagine10
RivistaSeminars in Oncology
Volume39
Stato di pubblicazionePublished - 2012

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

Causes of and prevention strategies for hepatocellular carcinoma. / Camma', Calogero; Cabibbo, Giuseppe; Genco, Chiara; Maida, Marcello Fabio; Antonucci, Michela.

In: Seminars in Oncology, Vol. 39, 2012, pag. 374-383.

Risultato della ricerca: Article

Camma', C, Cabibbo, G, Genco, C, Maida, MF & Antonucci, M 2012, 'Causes of and prevention strategies for hepatocellular carcinoma.', Seminars in Oncology, vol. 39, pagg. 374-383.
Camma', Calogero ; Cabibbo, Giuseppe ; Genco, Chiara ; Maida, Marcello Fabio ; Antonucci, Michela. / Causes of and prevention strategies for hepatocellular carcinoma. In: Seminars in Oncology. 2012 ; Vol. 39. pagg. 374-383.
@article{2e4e2591010940819fdfffaf3badbbd3,
title = "Causes of and prevention strategies for hepatocellular carcinoma.",
abstract = "Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behavior treatment and/or insulin-sensitizing drugs can be envisaged. Vaccination against HBV is the most efficient primary prevention measure currently available to reduce the HCC incidence and mortality in high-incidence areas, while data on the role of interferon (IFN) and nucleos(t)ide analogues (NUC) are still controversial. The pooling of data from the literature suggests a slight preventive effect of antiviral therapy on HCC development in patients with HCV-related cirrhosis, but the preventive effect is limited to sustained virological responders.",
keywords = "Hepatocellular carcinoma, chemoprevention, primary prevention",
author = "Calogero Camma' and Giuseppe Cabibbo and Chiara Genco and Maida, {Marcello Fabio} and Michela Antonucci",
year = "2012",
language = "Italian",
volume = "39",
pages = "374--383",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Causes of and prevention strategies for hepatocellular carcinoma.

AU - Camma', Calogero

AU - Cabibbo, Giuseppe

AU - Genco, Chiara

AU - Maida, Marcello Fabio

AU - Antonucci, Michela

PY - 2012

Y1 - 2012

N2 - Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behavior treatment and/or insulin-sensitizing drugs can be envisaged. Vaccination against HBV is the most efficient primary prevention measure currently available to reduce the HCC incidence and mortality in high-incidence areas, while data on the role of interferon (IFN) and nucleos(t)ide analogues (NUC) are still controversial. The pooling of data from the literature suggests a slight preventive effect of antiviral therapy on HCC development in patients with HCV-related cirrhosis, but the preventive effect is limited to sustained virological responders.

AB - Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behavior treatment and/or insulin-sensitizing drugs can be envisaged. Vaccination against HBV is the most efficient primary prevention measure currently available to reduce the HCC incidence and mortality in high-incidence areas, while data on the role of interferon (IFN) and nucleos(t)ide analogues (NUC) are still controversial. The pooling of data from the literature suggests a slight preventive effect of antiviral therapy on HCC development in patients with HCV-related cirrhosis, but the preventive effect is limited to sustained virological responders.

KW - Hepatocellular carcinoma

KW - chemoprevention

KW - primary prevention

UR - http://hdl.handle.net/10447/64621

M3 - Article

VL - 39

SP - 374

EP - 383

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

ER -